QQQ   272.87 (+0.37%)
TSLA   1,615.00 (+3.87%)
BA   174.00 (-0.82%)
QQQ   272.87 (+0.37%)
TSLA   1,615.00 (+3.87%)
BA   174.00 (-0.82%)
QQQ   272.87 (+0.37%)
TSLA   1,615.00 (+3.87%)
BA   174.00 (-0.82%)
QQQ   272.87 (+0.37%)
TSLA   1,615.00 (+3.87%)
BA   174.00 (-0.82%)
Log in

NASDAQ:REXNRexahn Pharmaceuticals Stock Price, Forecast & News

$2.45
-0.03 (-1.21 %)
(As of 08/13/2020 09:30 AM ET)
Add
Compare
Today's Range
$2.39
Now: $2.45
$2.67
50-Day Range
$2.48
MA: $2.76
$3.00
52-Week Range
$1.26
Now: $2.45
$4.26
Volume53,051 shs
Average Volume199,758 shs
Market Capitalization$9.85 million
P/E RatioN/A
Dividend YieldN/A
Beta0.98
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REXN
CUSIPN/A
Phone240-268-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.48 per share

Profitability

Net Income$-8,640,000.00

Miscellaneous

Employees10
Market Cap$9.85 million
Next Earnings Date8/19/2020 (Estimated)
OptionableOptionable
$2.45
-0.03 (-1.21 %)
(As of 08/13/2020 09:30 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REXN News and Ratings via Email

Sign-up to receive the latest news and ratings for REXN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rexahn Pharmaceuticals (NASDAQ:REXN) Frequently Asked Questions

How has Rexahn Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Rexahn Pharmaceuticals' stock was trading at $1.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, REXN shares have increased by 28.3% and is now trading at $2.45.
View which stocks have been most impacted by COVID-19
.

When is Rexahn Pharmaceuticals' next earnings date?

Rexahn Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 19th 2020.
View our earnings forecast for Rexahn Pharmaceuticals
.

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.61) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.95) by $0.34.
View Rexahn Pharmaceuticals' earnings history
.

When did Rexahn Pharmaceuticals' stock split? How did Rexahn Pharmaceuticals' stock split work?

Rexahn Pharmaceuticals shares reverse split before market open on Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 11th 2019. An investor that had 100 shares of Rexahn Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

Has Rexahn Pharmaceuticals been receiving favorable news coverage?

Media coverage about REXN stock has trended extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Rexahn Pharmaceuticals earned a news impact score of -4.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.
View the latest news about Rexahn Pharmaceuticals
.

Are investors shorting Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 364,900 shares, an increase of 254.3% from the January 31st total of 103,000 shares. Based on an average trading volume of 410,400 shares, the days-to-cover ratio is currently 0.9 days. Approximately 9.1% of the company's stock are sold short.
View Rexahn Pharmaceuticals' Short Interest
.

Who are some of Rexahn Pharmaceuticals' key competitors?

What other stocks do shareholders of Rexahn Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), CorMedix (CRMD), SLS International (SLS), Novavax (NVAX), AcelRx Pharmaceuticals (ACRX), Dynavax Technologies (DVAX), Celsion (CLSN), CytRx (CYTR) and Medallion Financial (MFIN).

Who are Rexahn Pharmaceuticals' key executives?

Rexahn Pharmaceuticals' management team includes the following people:
  • Douglas J. Swirsky, President, CEO, CFO, Secretary & Director
  • D J Kim, Vice President, Head-Research & Development
  • Lisa M. Nolan, Chief Business Officer

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the NASDAQ under the ticker symbol "REXN."

Who are Rexahn Pharmaceuticals' major shareholders?

Rexahn Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.40%). Company insiders that own Rexahn Pharmaceuticals stock include Ben Gil Price, Charles Beever, Douglas J Swirsky and Lisa Nolan.
View institutional ownership trends for Rexahn Pharmaceuticals
.

Which major investors are buying Rexahn Pharmaceuticals stock?

REXN stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Rexahn Pharmaceuticals stock in the last two years include Ben Gil Price, Charles Beever, Douglas J Swirsky, and Lisa Nolan.
View insider buying and selling activity for Rexahn Pharmaceuticals
.

How do I buy shares of Rexahn Pharmaceuticals?

Shares of REXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rexahn Pharmaceuticals' stock price today?

One share of REXN stock can currently be purchased for approximately $2.45.

How big of a company is Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals has a market capitalization of $9.85 million. Rexahn Pharmaceuticals employs 10 workers across the globe.

What is Rexahn Pharmaceuticals' official website?

The official website for Rexahn Pharmaceuticals is www.rexahn.com.

How can I contact Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. The company can be reached via phone at 240-268-5300 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.